PL2198007T3 - Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile - Google Patents

Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile

Info

Publication number
PL2198007T3
PL2198007T3 PL08830210T PL08830210T PL2198007T3 PL 2198007 T3 PL2198007 T3 PL 2198007T3 PL 08830210 T PL08830210 T PL 08830210T PL 08830210 T PL08830210 T PL 08830210T PL 2198007 T3 PL2198007 T3 PL 2198007T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
compositions containing
clostridium difficile
containing clostridium
difficile toxoids
Prior art date
Application number
PL08830210T
Other languages
English (en)
Inventor
C. Russell Middaugh
Richard Fahrner
Peter Ciarametaro
Original Assignee
Sanofi Pasteur Biologics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics, Llc filed Critical Sanofi Pasteur Biologics, Llc
Publication of PL2198007T3 publication Critical patent/PL2198007T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
PL08830210T 2007-09-14 2008-09-15 Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile PL2198007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97249607P 2007-09-14 2007-09-14
EP08830210.4A EP2198007B1 (en) 2007-09-14 2008-09-15 Pharmaceutical compositions containing clostridium difficile toxoids a and b
PCT/US2008/010767 WO2009035707A1 (en) 2007-09-14 2008-09-15 Pharmaceutical compositions containing clostridium difficile toxoids a and b

Publications (1)

Publication Number Publication Date
PL2198007T3 true PL2198007T3 (pl) 2018-03-30

Family

ID=40452372

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08830210T PL2198007T3 (pl) 2007-09-14 2008-09-15 Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile

Country Status (21)

Country Link
US (3) US9320790B2 (pl)
EP (3) EP3124044B8 (pl)
JP (3) JP5503543B2 (pl)
KR (2) KR20160005378A (pl)
CN (2) CN101855336B (pl)
AU (1) AU2008299885C1 (pl)
BR (1) BRPI0816790A8 (pl)
CA (1) CA2699435A1 (pl)
CY (1) CY1119979T1 (pl)
DK (1) DK2198007T3 (pl)
ES (2) ES3001561T3 (pl)
HR (1) HRP20180054T1 (pl)
HU (1) HUE037932T2 (pl)
IL (1) IL204366A (pl)
MX (1) MX2010002815A (pl)
NO (1) NO2198007T3 (pl)
PL (1) PL2198007T3 (pl)
PT (1) PT2198007T (pl)
RU (1) RU2550271C2 (pl)
SI (1) SI2198007T1 (pl)
WO (1) WO2009035707A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101855336B (zh) 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104903349B (zh) 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
MX361342B (es) 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
AU2014228983B2 (en) 2013-03-15 2018-04-05 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
WO2014144567A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
CN105611942A (zh) * 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
PL3010537T3 (pl) * 2013-06-17 2019-03-29 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Sposoby zapobiegania agregacji komponentów wirusowych
US9930893B2 (en) * 2014-02-10 2018-04-03 The Johns Hopkins University Inhibitors of DXP synthase and methods of use thereof
DK4268843T3 (da) 2014-11-07 2025-11-10 F Hoffmann La Roche Ltd Forbedrede IL-6-antistoffer
EP3294330A1 (en) 2015-05-15 2018-03-21 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
WO2017147293A1 (en) 2016-02-23 2017-08-31 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
WO2019225568A1 (ja) * 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
ZA927923B (en) * 1991-10-16 1993-04-26 Schering Corp Lipophilic oligosaccharide antibiotic salt compositions.
AU4646393A (en) 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
EP0877623A1 (en) * 1995-07-07 1998-11-18 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
PT892054E (pt) * 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
AU754270B2 (en) * 1997-10-20 2002-11-07 Sanofi Pasteur Biologics, Llc Passive immunization against clostridium difficile disease
EP1568378B1 (en) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
JP2000117967A (ja) * 1998-10-16 2000-04-25 Fuji Photo Film Co Ltd インクジェット記録方法
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6599715B1 (en) 1999-05-12 2003-07-29 The Regents Of The University Of California Real time viability detection of bacterial spores
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
WO2003088946A1 (en) * 2002-04-19 2003-10-30 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1686137A4 (en) 2003-10-09 2009-10-28 Chugai Pharmaceutical Co Ltd PROCESS FOR STABILIZING PROTEIN SOLUTIONS
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0613001B8 (pt) 2005-10-06 2021-05-25 Allergan Inc composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
US20090324647A1 (en) * 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
CN101855336B (zh) 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
KR20110100189A (ko) * 2008-12-03 2011-09-09 베링거잉겔하임베트메디카게엠베하 백신 생산 방법

Also Published As

Publication number Publication date
CN101855336B (zh) 2019-07-30
RU2010114730A (ru) 2011-10-20
BRPI0816790A2 (pt) 2014-10-14
EP2198007A1 (en) 2010-06-23
CY1119979T1 (el) 2018-12-12
AU2008299885B2 (en) 2014-12-11
CA2699435A1 (en) 2009-03-19
EP3124044B1 (en) 2024-12-18
EP3124044C0 (en) 2024-12-18
AU2008299885A1 (en) 2009-03-19
DK2198007T3 (en) 2018-01-15
US20180000920A1 (en) 2018-01-04
EP4537849A2 (en) 2025-04-16
EP2198007B1 (en) 2017-10-25
JP2010539172A (ja) 2010-12-16
JP6258674B2 (ja) 2018-01-10
EP4537849A3 (en) 2025-07-09
KR101679812B1 (ko) 2016-11-28
WO2009035707A1 (en) 2009-03-19
JP2014055174A (ja) 2014-03-27
US20110045025A1 (en) 2011-02-24
ES3001561T3 (en) 2025-03-05
CN101855336A (zh) 2010-10-06
US10639362B2 (en) 2020-05-05
ES2657485T3 (es) 2018-03-05
KR20100075912A (ko) 2010-07-05
US9320790B2 (en) 2016-04-26
BRPI0816790A8 (pt) 2017-05-16
NO2198007T3 (pl) 2018-03-24
WO2009035707A9 (en) 2010-06-10
IL204366A (en) 2013-02-28
PT2198007T (pt) 2018-01-29
MX2010002815A (es) 2010-07-30
JP5503543B2 (ja) 2014-05-28
KR20160005378A (ko) 2016-01-14
EP3124044B8 (en) 2025-01-22
HUE037932T2 (hu) 2018-09-28
EP3124044A1 (en) 2017-02-01
JP2017052773A (ja) 2017-03-16
CN106039299A (zh) 2016-10-26
AU2008299885C1 (en) 2015-06-25
HRP20180054T1 (hr) 2018-02-09
US20160317640A1 (en) 2016-11-03
US9687541B2 (en) 2017-06-27
RU2550271C2 (ru) 2015-05-10
SI2198007T1 (en) 2018-04-30
EP2198007A4 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
HUE037932T2 (hu) Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
IL220509A (en) Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
IL247741A0 (en) pharmaceutical preparations
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2001497A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2285357T3 (pl) Kompozycja farmaceutyczna zawierająca brivaracetam
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
HUE044237T2 (hu) Kortexolon-17-alfa-propionátot tartalmazó gyógyszerészeti kompozíciók
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2285413T3 (pl) Kompozycja farmaceutyczna
IL202306A (en) Pharmaceutical preparations containing stabilized thrombin
IL200313A0 (en) A lactase formulation
IL247086A0 (en) Nitrogen-containing compounds and pharmaceutical preparations
IL195039A0 (en) Pharmaceutical compositions containing oridonin
GB0712389D0 (en) A Pharmaceutical composition
GB0707127D0 (en) Pharmaceutical compositions
ZA201008115B (en) A solid pharmaceutical formulation
GB0709811D0 (en) Pharmaceutical compositions
GB2480585B (en) A tablet composition
GB0712454D0 (en) Pharmaceutical compositions
ZA201105447B (en) Compositions and dosage regimes comprising a clostridial vaccine and levamisole
HU0700755D0 (en) Pharmaceutical compositions containing capsaicionid
IL201394A0 (en) Niacin - based pharmaceutical compositions
GB0723018D0 (en) Pharmaceutical compositions
IL181181A0 (en) A pharmaceutical composition extracted from plants